Synthorx, Inc clinical trials
Acquired by Sanofi, Jan 23, 2020 · source ↗
The registry lists 1 studies whose lead sponsor is Synthorx, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 15, 2025.
- 1study on the registry
- 0open to participants now
Before and after it joined Sanofi
- First submitted before Synthorx, Inc became part of Sanofi
- 1
- First submitted after Synthorx, Inc became part of Sanofi
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Synthorx, Inc’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 1
All 1 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Stopped early1100%
Over the years
- 119
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Synthorx, Inc, a Sanofi company1 study
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All Sanofi studies →
- A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)TerminatedNCT04009681Phase 1/2
Sponsor listed in the registry: Synthorx, Inc, a Sanofi company · First submitted before Synthorx, Inc became part of Sanofi